Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: A single center experience

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 1, 2011, Pages 31-42

  Stratta, Piero ^a   Gravellone, Luciana ^a   Cena, Tiziana ^a   Rossi, Davide ^a   Gaidano, GianLuca ^a   Fenoglio, Roberta ^a   Lazzarich, Elisa ^a   Quaglia, Marco ^a   Airoldi, Andrea ^a   Bozzola, Cristina ^a   Monga, Guido ^a   Valente, Guido ^a   Canavese, Caterina ^a   Magnani, Corrado ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Albuminuria; Bence Jones proteinuria; Diabetes; Elderly patients; Glomerular proteinuria; Monoclonal component; Monoclonal immunoglobulin deposition disease; Myeloma; Paraproteinemia; Renal failure

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; PARAPROTEIN;

ADULT; AGED; AGING; AMYLOIDOSIS; ARTERIOLOSCLEROSIS; BLOOD DYSCRASIA; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULONEPHRITIS; HEAVY CHAIN DISEASE; HUMAN; IMMUNOGLOBULIN DEPOSITION; IMMUNOGLOBULIN LIGHT CHAIN DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PARAPROTEINEMIA; PROTEINURIA; REVIEW; RISK FACTOR; URINARY CAST;

AGED; BLOOD CELLS; HUMANS; KIDNEY DISEASES; MULTIPLE MYELOMA; PARAPROTEINEMIAS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79957931026     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.05.001     Document Type: Review

References (52)

1. Solomon A., Weiss D.T. Ominous consequences of immunoglobulin deposition. N Engl J Med 1993, 329:1422-1423.
2. Buxbaum J.N. Abnormal immunoglobulin synthesis in monoclonal light chain and light and heavy chain deposition disease. Amyloid 2001, 8:84-93.
3. Merlini G.P., Stone M.J. Dangerous small B-cell clones. Blood 2006, 108:2520-2530.
4. Ronco P., Plaisier E., Mougenot B., Aucouturier P. Immunoglobulin light (heavy) chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006, 1:1342-1350.
5. Herrera G.A. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol 2000, 4:174-200.
6. Lin J., Markowitz G.S., Valeri A.M., et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001, 12:1482-1492.
7. Markowitz G.S. Dysproteinemia and the Kidney. Adv Anat Pathol 2004, 11:49-63.
8. Merlini G., Pozzi C. Mechanisms of renal damage in plasma cell dyscrasias: an overview. Contrib Nephrol 2007, 153:66-86.
9. Gertz M.A., Lacy M.Q., Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999, 13:1211-1213.
10. Gertz M.A., Lacy M.Q., Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 2002, 61:1-9.
11. Abraham R.S., Geyer S.M., Price-Troska T.L., et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003, 101:3801-3808.
12. Alpers C.E., Smith K.D. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008, 17:243-249.
13. Roccatello D., Fornasieri A., Giachino O., et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007, 49:69-82.
14. Picken M.M., Shen S. Immunoglobulin light chains and the kidney: an overview. Ultrastuct Pathol 1994, 18:105-112.
15. Moulin B., Deret S., Mariette X., et al. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. J Am Soc Nephrol 1999, 10:519-528.
16. Ronco P.M., Alyanakian M.A., Mougenot B., Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at molecular level. J Am Soc Nephrol 2001, 12:1558-1565.
17. Pozzi C., D'Amico M., Fogazzi G.B., et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003, 42:1154-1163.
18. Keeling J., Herrera G.A. The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 2007, 153:116-134.
19. Teng J., Russell W.J., Gu X., Cardelli J., Jones M.L., Herrera G.A. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004, 84:440-451.
20. Cooper E.H., Forbes M.A., Crockson R.A., MacLennan I.C. Proximal renal tubular function in myelomatosis: observation in the fourth Medical Research Council trial. J Clin Pathol 1984, 37:852-858.
21. Markowitz G.S., Flis R.S., Kambham N., D'Agati V.D. Fanconi syndrome with free kappa light chains in the urine. Am J Kidney Dis 2000, 4:777-781.
22. Messiaen T., Deret S., Mougenot B., Bridoux F., Dequiedt P., Dion J.J. Adult Fanconi Syndrome secondary to light chain gammopathy. Medicine (Baltimore) 2000, 79:135-154.
23. Sanders P.W., Booker B.B., Bishop J.B., Cheung H.C. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992, 89:630-639.
24. Huang Z.-Q., Sanders P.W. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Inv 1995, 73:810-817.
25. Leboulleux M., Lelongt B., Mougenot B., et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995, 48:72-79.
26. Huang Z.Q., Sanders P.W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Inv 1997, 99:732-736.
27. Herrera G.A., Sanders P.W. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib Nephrol 2007, 153:105-115.
28. Rota S., Mougenot B., Baudouin B., et al. Multiple myeloma and severe renal failure: a clinico-pathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987, 66:126-129.
29. Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma. Arch Int Med 1990, 150:1693-1695.
30. Bataille R., Harousseau J. Multiple myeloma. N Engl Med 1997, 336:1657-1664.
31. Irish A.B., Winearls C.G. Presentation and survival of patients with severe renal failure and myeloma. Q J Med 1997, 90:773-780.
32. Bladé J., Fernández-Llama P., Bosch F., et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998, 158:1889-1893.
33. Chow C.C., Mo K.L. Renal impairment in patients with multiple myeloma. Hong Kong Med J 2003, 9:78-82.
34. Sirohi B., Powles S. Multiple myeloma. Lancet 2004, 363:875-887.
35. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-56.
36. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
37. Kyle R.A. " Benign" monoclonal gammopathy - after 20 to 35 years of follow up. Mayo Clin Proc 1993, 68:26-36.
38. Sanders P.W. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 1994, 124:484-488.
39. Ballester O.F., Tummala R., Janssen W.E., et al. High dose chemotherapy and autologous peripheral blood steam cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transpl 1997, 20:653-656.
40. Barosi G., Boccadoro M., Cavo M., et al. Management of multiple myeloma and related disorders: guidelines from the Italian Society of Hematology and Italian group for Bone Marrow Transplantation. Haematologica 2004, 89:717-741.
41. Royer B., Arnulf B., Martinez F., et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004, 65:642-648.
42. Jennette J.C., Heptinstall R.H. Heptinstall's pathology of the kidney 2007, Lippincott Williams & Wilkins, Philadelphia, PA.
43. Maclennan I.C.M., Drayson D., Dunn J. Multiple myeloma. Br Med J 1994, 308:1033-1036.
44. Pascali E. Bence Jones protein in primary systemic amyloidosis. Blood 1993, 81:564-565.
45. Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991, 324:1845-1851.
46. Paueksakon P., Revelo M.P., Horn R.G., Shappell S., Fogo A.B. Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003, 42:87-95.
47. Ganeval D., Lacour B., Chopin N., Grünfeld J.P. Proteinuria in multiple myeloma and related diseases. Am J Nephrol 1990, S1:S58-S62.
48. Lee M.T., Parwani A., Humphrey R., Hamilton R.G., Myers D.I., Detrick B. Gamma heavy chain disease in a patient with diabetes and chronic renal insufficiency: diagnostic assessment of the heavy chain fragment. J Clin Lab Anal 2008, 22:146-150.
49. Santostefano M., Zanchelli F., Zaccaria A., Poletti G., Fusaroli M. The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 2005, 18:659-675.
50. Heilig C.W., Brosius F.C., Cunningham C. Role for GLUT1 in diabetic glomerulosclerosis. Expert Rev Molecular Med 2006, 8(4):1-18.
51. Liu S., Shi L., Wang S. Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury. Am J Physiol Renal Physiol 2007, 293:F1727-F1735.
52. Lin C.L., Wang F.S., Kuo Y.R., et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 2006, 69:1593-1600.